Completed Trials Post 11% Drop In 2025

By Drew Muscara and Alex Noll

Fewer trials, stronger outcomes. This report reveals a clear shift toward quality over quantity, with sponsors achieving higher rates of success across the industry. Here, we examine the top 3 therapeutic areas: assessment by top sponsors, diseases with positive pivotal trials, and Pipeline Therapeutics. From breakthroughs in cancer and immune-mediated diseases to the growing momentum behind metabolic research, the analysis highlights where development efforts are translating into meaningful clinical progress.